Abstract:3629 The epidermal growth factor receptor (EGFR) plays a critical role in cell growth and differentiation through the EGFR signaling pathway and is believed to be related to development and progression of lung cancer. The EGFR signaling pathway encompasses several steps including ligand binding to the cell surface receptor, receptor dimerization, tyrosine kinase (TK) activation, nuclear translation and transcriptional regulation. Recently, studies have revealed that never smoking lung cancer patients who have somatic mutations in the TK domain of EGFR have a dramatic response to gefitinib, an inhibitor of the EGFR-TK. To elucidate how common EGFR-TK domain mutations are in never smoking lung cancer patients compared to smoking patients, we sequenced the EGFR gene in exons 18-21 (the EGFR-TK domain) from lung tumor tissues of smokers and never smokers. A point mutation in the TK domain of EGFR was found in five of 35 never smokers (frequency of 14.2%), but no mutation was detected in 18 smokers. Mutations found in never smokers included: three heterozygous point mutations at T2573G (L858R) in exon 21, one point mutation at G2320A (V774M) in exon 20, and another point mutation at T2497G (L833V) in exon 21. By sequencing 16 lung cancer cell lines derived from smokers available in our laboratory, one mutant cell line (273T) harboring a EGFR-TK mutation has been identified: A2180G (Y727C) in exon 18, in cells derived from a squamous cell tumor of a female smoker. The in vitro sensitivity to gefitinib by MTT assay of the 273T cell line was slightly lower (IC50 of 17μM) compared to wildtype (WT) cell lines (IC50 of 30μM). This cell line also shows a higher (6-fold) EGFR expression by immunoblot compared to WT cell lines cultured in normal growth medium. During sequencing of the TK domain in blood samples, lung fibroblasts and tumor specimens, a polymorphism in EGFR, G2361A in exon 20, was identified and found to occur at a significantly higher frequency in lung cancer cases (n = 96) than in controls ( n = 32)[OR: 2.86, 95% CI: 1.02 -8.06, P = 0.04], but no difference in the polymorphism frequency was found between smoking (n = 21) and never smoking (n =35) lung cancer cases (OR: 1.78, 95% CI: 0.32 -9.79, P = 0.503). This may suggest that individuals who carry at least one copy of the A allele at nucleotide 2361 in the EGFR-TK domain are more susceptible to lung cancer, independent of smoking status. In addition, homozygote for the A allele at nucleotide 2361 was also most common in lung cancer cases (frequency of 53.7%) vs. controls (frequency of 21.9%). This study confirms the more frequent rate of EGFR-TK domain mutation in never smokers with lung cancer than in smokers, but suggests that EGFR mutation may sometimes occur in smokers, and suggests a novel polymorphism in the EGFR-TK domain may be related to lung cancer risk. Supported by 5R25 CA89507 and P50 CA090440, SPORE in Lung Cancer.

-216G/T (rs712829), a Functional Variant of the EGFR Promoter, is Associated with the Pleural Metastasis of Lung Adenocarcinoma.

Nucleotide Excision Repair Gene ERCC1 19007T>C Polymorphism Contributes to Lung Cancer Susceptibility: A Meta-Analysis

Variation in the EGFR Gene is Associated with Lung Cancer

Mutation and Polymorphism in the EGFR-TK Domain Associated with Lung Cancer

Discriminating Association of a Common Telomerase Reverse Transcriptase Promoter Polymorphism with Telomere Parameters in Non-Small Cell Lung Cancer with or Without Epidermal Growth Factor Receptor Mutation.

A functional polymorphism (-1607 1G→2G) in the matrix metalloproteinase-1 promoter is associated with development and progression of lung cancer.

Prognostic Implications of the EGFR Polymorphism Rs763317 and Clinical Variables among Young Chinese Lung Cancer Population.

TERTPolymorphism Rs2736100-C is Associated with EGFR Mutation–Positive Non–Small Cell Lung Cancer

Polymorphisms in epidermal growth factor receptor (EGFR) and AKT1 as possible predictors of clinical outcome in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors

The functional SNP in the matrix metalloproteinase-3 promoter modifies susceptibility and lymphatic metastasis in esophageal squamous cell carcinoma but not in gastric cardiac adenocarcinoma.

P1.01-85 the Prevalence of Different EGFR Exon20 Mutations in 12,833 Chinese Lung Cancer Patients

Association of genetic polymorphisms of EGFR with glioma in a Chinese population.

An Association Between EGF and EGFR Gene Polymorphisms with Gastric Cancer in a Chinese Han Population

Cmar_a_200126 6139..6150

TLR4 Promoter Rs1927914 Variant Contributes to the Susceptibility of Esophageal Squamous Cell Carcinoma in the Chinese Population

Polymorphisms in the MMP1 and MMP3 Promoter and Non-Small Cell Lung Carcinoma in North China.

Epidemiology and Prevention-A Functional Polymorphism in the Matrix Metalloproteinase-2 Gene Promoter (-1306C/T) Is Associated with Risk of Development but not Metastasis of …

The Involvement of Kras Gene 3'-UTR Polymorphisms in Risk of Cancer and Influence on Patient Response to Anti-Egfr Therapy in Metastatic Colorectal Cancer: a Meta-Analysis

A Functional Polymorphism In The Matrix Metalloproteinase-2 Gene Promoter (-1306c/T) Is Associated With Risk Of Development But Not Metastasis Of Gastric Cardia Adenocarcinomal

P2.03-12 EGFR and ERBB2 Germline Mutations in Chinese Lung Cancer Patients and Their Roles in Genetic Susceptibility to Cancer

Functional genetic variants of TNFSF15 and their association with gastric adenocarcinoma: a case-control study.